Clinical progress of residual neuromuscular block in obese patients

doi:10.3877/cma.j.issn.2095-9605.2022.01.011

Abstract

Abstract:

The perioperative management of obese patients has always been the focus of anesthesiologists, and residual neuromuscular block is associated with a variety of adverse events, reducing the incidence of residual neuromuscular block will effectively improve the quality of postoperative rehabilitation and reduce the incidence of perioperative complications in obese patients.This paper will introduce the current clinical research progress of residual neuromuscular block in obese patients from the aspects of evaluation methods and standards of residual neuromuscular block, pathophysiological changes of respiratory system in obese patients, relevant factors affecting the incidence of residual neuromuscular block in obese patients, and how to prevent residual neuromuscular block in obese patients.

Key words: Residual neuromuscular block, Obesity, Nondepolarizing muscle relaxant, Sugammadex, Perioperative management

Qichen Luo, Yalan Li. Clinical progress of residual neuromuscular block in obese patients[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2022, 08(01): 61-65.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2022.01.011

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2022/V08/I01/61

References 48

[1]	NCD-RisCNRFC. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants [J]. Lancet, 2016, 10026(387): 1377-1396.
[2]	Saager L, Maiese EM, Bash LD, et al. Incidence, risk factors, and consequences of residual neuromuscular block in the United States: The prospective, observational, multicenter RECITE-US study [J]. J Clin Anesth, 2019, 55: 33-41.
[3]	Ali H, Utting J, Gray C. Stimulus frequency in the detection of neuromuscular block in humans [J]. Br J Anaesth, 1970,42: 967-978.
[4]	Sundman E, Witt H, Olsson R. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans Pharyngeal videoradiography and simultaneous manometry after atracurium [J]. Anesthesiology, 2000, 92(4): 977-984.
[5]	Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block [J]. Anesth Analg, 2010, 111(1): 120-128.
[6]	Murphy GS. Neuromuscular monitoring in the perioperative period [J]. Anesth Analg, 2018, 126(2): 464-468.
[7]	Murphy GS, Szokol JW, Marymont JH, et al. Residual paralysis at the time of tracheal extubation [J]. Anesth Analg, 2005, 100(6): 1840-1845.
[8]	Jones RL, Nzekwu MM. The effects of body mass index on lung volumes [J]. Chest, 2006, 130(3): 827-833.
[9]	Ashburn DD, DeAntonio A, Reed MJ. Pulmonary system and obesity [J]. Crit Care Clin, 2010, 26(4): 597-602.
[10]	Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults [J]. N Engl J Med, 1993, 328(17): 1230-1235.
[11]	Murugan AT, Sharma G. Obesity and respiratory diseases [J]. Chron Respir Dis, 2008, 5(4): 233-242.
[12]	Baillard C, Gehan G, Reboul-Marty J, et al. Residual curarization in the recovery room after vecuronium [J]. Br J Anaesth, 2000, 84(3): 394-395.
[13]	Bissinger U, Schimek F, Lenz G. Postoperative residual paralysis and respiratory status: a comparative study of pancuronium and vecuronium [J]. Physiol Res, 2000, 49(4): 455-462.
[14]	Hayes AH, Mirakhur RK, Breslin DS, et al. Postoperative residual block after intermediate-acting neuromuscular blocking drugs [J]. Anaesthesia, 2001, 56(4): 312-318.
[15]	McCaul C, Tobin E, Boylan J, et al. Atracurium is associated with postoperative residual curarization [J]. Br J Anaesth, 2002, 89(5): 766-769.
[16]	Kim KS, Lew SH, Cho HY, et al. Residual paralysis induced by either vecuronium or rocuronium after reversal with pyridostigmine [J]. Anesth Analg, 2002, 95(6): 1656-1660.
[17]	Ga Tke M, Viby-Mogensen J, Rosenstock C, et al. Postoperative muscle paralysis after rocuronium: less residual block when acceleromyography is used [J]. Acta Anaesthesiol Scand, 2002, 46(2): 207-213.
[18]	Baillard C, Clec HC, Catineau J, et al. Postoperative residual neuromuscular block: a survey of management [J]. Br J Anaesth, 2005, 95(5): 622-626.
[19]	Kopman AF, Zank LM, Ng J, et al. Antagonism of cisatracurium and rocuronium block at a tactile train-of-four count of 2: should quantitative assessment of neuromuscular function be mandatory? [J]. Anesth Analg, 2004, 98(1): 102-106.
[20]	Murphy GS, Szokol JW, Franklin M, et al. Postanesthesia care unit recovery times and neuromuscular blocking drugs: a prospective study of orthopedic surgical patients randomized to receive pancuronium or rocuronium [J]. Anesth Analg, 2004, 98(1): 193-200.
[21]	Cammu G, De Witte J, De Veylder J, et al. Postoperative residual paralysis in outpatients versus inpatients [J]. Anesth Analg, 2006, 102(2): 426-429.
[22]	Maybauer D, Geldner G, Blobner M, et al. Incidence and duration of residual paralysis at the end of surgery after multiple administrations of cisatracurium and rocuronium [J]. Anaesthesia, 2007, 62(1): 12-17.
[23]	Murphy GS, Szokol JW, Marymont JH, et al. Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit [J]. Anesthesiology, 2008, 109(3): 389-398.
[24]	Thomas R, Smith D, Strike P. Prospective randomised double-blind comparative study of rocuronium and pancuronium in adult patients scheduled for elective "fast-track" cardiac surgery involving hypothermic cardiopulmonary bypass [J]. Anaesthesia, 2003, 58(3): 265-271.
[25]	Lemmens HJM, Brodsky JB. The Dose of Succinylcholine in Morbid Obesity [J]. Anesthesia & Analgesia, 2006, 102(2): 438-442.
[26]	Schwartz AE, Matteo RS, Ornstein E, et al. Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient [J]. Anesthesia and analgesia, 1992, 74(4): 515-518.
[27]	Van Kralingen S, Van De Garde E. Comparative evaluation of atracurium dosed on ideal body weight vs total body weight in morbidly obese patients [J]. British Journal of Clinical Pharmacology, 2011, 71(1): 34-40.
[28]	Murphy GS. Pro: Deep neuromuscular blockade should be maintained during laparoscopic surgery [J]. Anaesth Crit Care Pain Med, 2021, 40(4): 100918.
[29]	Raval AD, Deshpande S, Rabar S, et al. Does deep neuromuscular blockade during laparoscopy procedures change patient, surgical, and healthcare resource outcomes? A systematic review and meta-analysis of randomized controlled trials [J]. PLoS One, 2020, 15(4): 231452.
[30]	Murphy GS, Avram MJ, Greenberg SB, et al. Neuromuscular and clinical recovery in thoracic surgical patients reversed with neostigmine or sugammadex [J]. Anesth Analg, 2021, 133(2): 435-444.
[31]	Togioka B, Yanez D, Aziz M, et al. Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery [J]. Br J Anaesth, 2020, 124(5): 553-561.
[32]	Gaszynski T, Szewczyk T, Gaszynski W. Randomized comparison of sugammadex and neostigmine for reversal of rocuronium-induced muscle relaxation in morbidly obese undergoing general anaesthesia [J]. Br J Anaesth, 2012, 108(2): 236-239.
[33]	Mostoller K, Wrishko R, Maganti L, et al. Pharmacokinetics of sugammadex dosed by actual and ideal body weight in patients with morbid obesity undergoing surgery [J]. Clin Transl Sci, 2021, 14(2): 737-744.
[34]	Abd EA, Othman AH, El SF, et al. Comparison of three different doses sugammadex based on ideal body weight for reversal of moderate rocuronium-induced neuromuscular blockade in laparoscopic bariatric surgery [J]. Minerva Anestesiol, 2017, 83(2): 138-144.
[35]	Loupec T, Frasca D, Rousseau N, et al. Appropriate dosing of sugammadex to reverse deep rocuronium-induced neuromuscular blockade in morbidly obese patients [J]. Anaesthesia, 2016, 71(3): 265-272.
[36]	Li D, Wang Y, Zhou Y, et al. Efficacy and safety of sugammadex doses calculated on the basis of corrected body weight and total body weight for the reversal of deep neuromuscular blockade in morbidly obese patients [J]. J Int Med Res, 2021, 49(1): 1-12.
[37]	Horrow J, Li W, Blobner M, et al. Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: a randomized clinical trial [J]. BMC Anesthesiol, 2021, 21(1): 62.
[38]	Murphy GS, Szokol JW, Marymont JH, et al. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit [J]. Anesth Analg, 2008, 107(1): 130-137.
[39]	Murphy GS, Szokol JW, Avram MJ, et al. Postoperative residual neuromuscular blockade is associated with impaired clinical recovery [J]. Anesth Analg, 2013, 117(1): 133-141.
[40]	Thorell A, MacCormick AD, Awad S, et al. Guidelines for perioperative care in bariatric surgery: enhanced recovery after surgery (eras) society recommendations [J]. World J Surg, 2016, 40(9): 2065-2083.
[41]	Nightingale CE, Margarson MP, Shearer E, et al. Peri-operative management of the obese surgical patient 2015: Association of Anaesthetists of Great Britain and Ireland Society for Obesity and Bariatric Anaesthesia [J]. Anaesthesia, 2015, 70(7): 859-876.
[42]	Brull SJ, Murphy GS. Residual neuromuscular block: lessons unlearned Part II: methods to reduce the risk of residual weakness [J]. Anesth Analg, 2010, 111(1): 129-140.
[43]	Dobson GR. Special announcement: Guidelines to the practice of anesthesia-revised edition 2020 [J]. Can J Anaesth, 2020,67(1):1-8.
[44]	Réka N, Ross JR. Clinical practice guideline for the management of neuromuscular blockade: what are the recommendations in the USA and other countries [J]. Current Anesthesiology Reports, 2020, 10(2): 90-98.
[45]	Murphy GS, Szokol JW, Marymont JH, et al. Recovery of neuromuscular function after cardiac surgery: pancuronium versus rocuronium [J]. Anesth Analg, 2003, 96(5): 1301-1307.
[46]	Fuchs-Buder T, Hofmockel R, Geldner G, et al. The use of neuromuscular monitoring in Germany [J]. Anaesthesist, 2003, 52(6): 522-526.
[47]	Carron M, Veronese S, Foletto M, et al. Sugammadex allows fast-track bariatric surgery [J]. Obes Surg, 2013, 23(10): 1558-1563.
[48]	Grayling M, Sweeney BP. Recovery from neuromuscular blockade: a survey of practice [J]. Anaesthesia, 2007, 62(8): 806-809.

Please choose a citation manager

Content to export